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Abstract
Introduction: Chronic inflammation in asthmatic airways leads to bronchial hyper-responsiveness (BHR) and the develop-
ment of structural changes. Important features of remodeling include the formation of subepithelial fibrosis due to increased
collagen deposition in the reticular basement membrane. Transforming growth factor (TGF)-β might be a central mediator
of tissue fibrosis and remodeling.
Materials and Methods: Immunohistochemistry was used to measure collagen III deposition and TGF-β1 expression in biop-
sies from patients with long-standing asthma treated with inhaled corticosteroids, patients with recently diagnosed asthma,
and control subjects. Computer-assisted image analysis was used to evaluate total basement membrane (TBM) thickness.
Results: Asthmatics, particularly those with long-standing asthma, had thicker TBMs than healthy subjects. Collagen III
deposition was comparable in the studied groups. BHR was not correlated with features of mucosal inflammation and was
lower in steroid-treated patients with long-standing asthma than in subjects with newly diagnosed asthma untreated with
steroids. Epithelial TGF-β1 expression negatively correlated with collagen III deposition and TBM thickness. 
Conclusions: The study showed that TBM thickness, but not collagen III deposition, could be a differentiating marker of asth-
matics of different disease duration and treatment. The lack of correlation between BHR and features of mucosal inflam-
mation suggests the complexity of BHR development. Corticosteroids can reduce BHR in asthmatics, but it seems to be less
effective in reducing subepithelial fibrosis. The role of epithelial TGF-β1 needs to be further investigated since the possibil-
ity that it plays a protective and anti-inflammatory role in asthmatic airways cannot be excluded.
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INTRODUCTION
Airway inflammation and bronchial hyper-respon-
siveness (BHR) are the hallmarks of asthma. The inflam-
matory changes are regarded as a key factor in BHR;
however, the relationships between inflammation mark-
ers and BHR are not clear, with comparable numbers of
reports showing or denying such relationships. Structural
changes in the airways are thought to be involved in the
development of BHR, particularly in long-standing dis-
ease, but the relationship between remodeling features
and BHR needs to be further investigated. Impaired
functioning of the hypothetical epithelial-mesenchymal
trophic unit is thought to play an important role in
remodeling pathogenesis [16]. The process of the devel-
opment of structural changes is thought to be responsible
for the irreversible airway obstruction. One of the most
prominent histopathological features of remodeling is
subepithelial fibrosis due to the deposition of anumber of
extracellular matrix (ECM) proteins, including collagensI, III, and V, fibronectin, tenascin, and proteoglycans in
the reticular basement membrane (RBM) [29]. Although
these features are well recognized, the mechanisms lead-
ing to remodeling and the effect of therapy on preventing
or reversing these changes are not well understood.
A number of different cells and mediators are involved in
airway inflammation and remodeling, forming a complex
network of multidirectional reactions. It has been postu-
lated that transforming growth factor (TGF)-β is one of
the important mediators involved in allergic inflamma-
tion and remodeling. It is thought to be involved in the
downregulation of activated inflammatory cells, tissue
differentiation, and wound healing. In the airways, TGF-β
is found in various cell types, including epithelial cells and
inflammatory cells beneath the basement membrane.
There is speculation about various TGF-β functions at its
different locations [21]. There are also contradictory data
as to the distribution of TGF-β in the airways of asthmat-
ics. All these discrepancies were reasons to carry out the
present study. We investigated BHR, subepithelial fibro-
sis, features of mucosal inflammation, and TGF-β1
expression in patients with different asthma durations
and different applied treatments.
MATERIALS AND METHODS
Subjects
Thirty-four patients with asthma fulfilling the crite-
ria of the Global Initiative for Asthma of the
NHLBI/WHO were recruited (Table 1). They were fur-
ther divided into two groups: the long-standing asthma
group (LSA), with 16 subjects with asthma duration of
at least 4 years treated with inhaled corticosteroids
(ICS), and the recently diagnosed asthma group (RDA),
with 18 subjects with asthma duration of less than 4
years untreated with ICS. The control group consisted
of 13 subjects with no history of asthma (Table 1). The
study was approved by the Ethics Committee of the
Wroc³aw Medical University and written informed con-
sent was obtained from all subjects before entry into the
study.
Lung function and challenge procedure
Pulmonary function tests included three measure-
ments of FEV1, FEV1/FVC, and PEF with a flow-screen
spirometer (Jaeger GMBH & CoKH, Germany). The
reversibility of airway obstruction was investigated in
response to inhaled salbutamol. Histamine challenge
tests were carried out using computer software with
a special protocol developed at the Department of
Internal Medicine and Allergology, Wroc³aw Medical
University [20], with a De Vilbiss 646 nebulizer.
Fiberoptic bronchoscopy
Bronchoscopy was performed according to BTS
guidelines [7]. The subjects were premedicated with 0.5
mg atropine s.c. and 25 mg pethidine i.v. During bron-
choscopy, visual assessment of airway inflammation was
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Table 1. Subjects’ characteristic
LSA group  RDA group Controls
n=16 n=18 n=13
Age (years)* 49.10±15.50 41.6±13.5 46.92±14.7
Sex: F/M 15/1 17/1 10/3
Asthma duration (years) 14.50±12.70 1.7±1.3 –
Asthma severity: 
mild 8 (50%) 16 (88.8%) –
moderate 5 (31.2%) 2 (11.1%) –
severe 3 (18.7%) 0 –
Atopy/no atopy 9/7 8/10 2/11
PC20 (mg/ml)  8.89±6.40 4.68±2.9 >16
FEV1 (% pred. value) 85.75±19.40 99.3±17.4 109.79±9.1
PEF (% pred. value) 67.27±18.20 86.5±23.1 88.6±12.4
FEV1%FVC 75.72±13.57 79.34±8.8 82.4±10.0
ICS doses:**
small: 200–600 µg/die 16.6% – –
moderate: 600–1000 µg/die 41.6% – –
large: ≥1000 µg/die 41.6% – –
ICS use length (years):
range/mean 1–12.5/(4.9±3.58) – –
Smoking cigarettes history
positive (%) (always <10 pack-years) 18.7% 22.2% 0%
ICS – inhaled corticosteroids, LSA – long–standing asthmatics treated with ICS, RDA – recently diagnosed asthmatics untreated
with ICS.
* Values are expressed as means ±SEMs, except for cases where showed differently, **ICS dose during last 3 months (budesonide).done and the macroscopic bronchitis index was derived
(0–3 scale) depending on the presence of abnormal
mucosal features [28]. Two to three biopsies were col-
lected from the subcarinae of the right upper lobe using
a Pentax FB18X bronchoscope, fixed in formalin solu-
tion, and embedded in paraffin. 
Tissue processing and immunohistochemistry
Biopsy specimens coded prior to analysis were stud-
ied histologically and immunohistochemically. A histo-
pathologist assessed the features of mucosal inflamma-
tion and on that basis the microscopic inflammation
index was introduced. This index was used to differenti-
ate the degree of mucosal inflammation in the biopsies
and to compare it with the macroscopic inflammation
index (bronchitis index according to Thompson et al.
[28]). The microscopic inflammation index was evaluat-
ed semiquantitatively by the histopathologist on the
basis of the presence of inflammatory cells in the
mucosa (1 – small inflammation, 2 – moderate, 3 – large
degree of inflammation).
For immunohistochemistry, the sections were stained
using the streptavidin-biotin-peroxidase technique [26].
To assess TGF-β1 and collagen type III expression the
sections were incubated with a mouse anti-TGF-β1 mon-
oclonal antibody (dilution 1:20, Novo Castra
Laboratories, England) and with a mouse anti-collagen
III monoclonal antibody (dilution 1:100, Medicorp,
Canada), respectively. All the sections were then incu-
bated with biotinylated antibody (LSAB Kit, Dako,
USA) and with a streptavidin-biotin-peroxidase complex
(LSAB Kit, Dako, USA). They were subsequently devel-
oped in 3,3-diaminobenzidine (DAB, Liquid K, Dako,
US). Skin samples were used as a positive control for
anti-collagen III antibodies and the placenta for anti-
TGF-β1 antibodies. Sections in which the primary anti-
bodies were omitted served as a negative control.
Immunohistochemical staining was assessed with an
Olympus BH-2 light microscope at a magnification of
200× in a semiquantitative analysis with the visual scale.
Two parameters were used to determine TGF-β1 expres-
sion and collagen type III deposition within the epitheli-
um and subepithelial area in the airways. The first was the
extent of the tissue area which was stained immunohisto-
chemically and is presented as the percentage of the total
tissue area and the second was the intensity of the
immunohistochemical staining. Both were assessed semi-
quantitatively. The staining intensity was assessed on
a scale of 0 to 3 (0 – no expression, 1 – poor expression, 2
– moderate expression, 3 – strong expression). Both these
parameters correlated positively with each other. 
Total basement membrane (TBM) thickness (the
“true” basement membrane and RBM together) was
assessed on sections stained with toluidine blue using
a Multiscan 08.98 computer-assisted image analysis sys-
tem, making 10 measurements for each patient along
the basement membrane from the base of the epitheli-
um to the outer limit of the RBM.
Statistical analysis
MS EXCEL software was used for the statistical
analysis. Results are given as the mean ±SD. Of the
analyzed features, BHR, TBM, and collagen III deposi-
tion had normal distributions, while epithelial and
subepithelial TGF-β1 expressions were right-skewed, so
a logarithmic transformation was used. Student’s t-test
was applied to compare two groups and the chi-squared
test to assess the frequency in the groups. Additionally,
Fisher’s exact test as well as Scheffe’s and Levene’s tests
were performed.
RESULTS
The groups did not differ with regard to age or sex.
Lung function parameters were significantly lower in
the LSA group than in the RDA group (FEV1%:
p=0.039, FVC%: p=0.012). Patients with asthma
showed a negative correlation between FEV1 and asth-
ma duration (p=0.004; Fig. 1). 
The mean PC20 value in all asthmatics was
6.58±5.24 mg/ml. Mean PC20 was significantly lower in
the RDA group than in the LSA group (p=0.02; Table
1). A significant positive correlation between PC20 val-
ues and ICS treatment duration was observed (p<0.05;
Fig. 2). No correlations were found between PC20 val-
ues and spirometric indices, asthma duration, TGF-β1
expression,TBM thickness, or collagen type III mucosal
expression. PC20 values were not significantly differen-
tiated with regard to microscopic or macroscopic fea-
tures of mucosal inflammation.
The patients with asthma had thicker TBM (mean:
8.56±3.11 µm) than the control subjects (3.25±0.96 µm;
p<0.001; Table 2). Moreover, in spite of steroid treat-
ment, there was significantly thicker TBM in the LSA
group than in the RDA group (Table 2). Significant pos-
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Fig. 1. Scatterplot: astma duration (ln) vs. FEV1.
r = -0.4849 p = 0.004
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95% confidenceitive correlation was found between TBM thickness and
asthma duration (p=0.004; Fig. 3). There was no clear
correlation between TBM thickness and lung function
(FEV1).
The expression of collagen type III in the subepithe-
lial area was similar in the studied groups (Table 2). No
correlations were found between collagen III deposition
and lung function. There were also no significant corre-
lations observed between TBM thickness and collagen
III deposition.
TGF-β1 was rarely expressed in the epithelial cells of
asthmatic airways, particularly in the LSA group com-
pared with control subjects (Table 3), although these dif-
ferences were not statistically significant. In the LSA
group, negative correlation was found between TGF-β1
epithelial expression and collagen III deposition (p=0.03;
Fig. 4) and TBM thickness (p=0.05; Fig. 5). In the RDA
group, positive correlation between epithelial TGF-β1
expression and lung function was observed (Fig. 6).
Examples of bronchial mucosal biopsies stained with
toluidine blue and antibodies to collagen type III are
shown in Figs. 7–11.
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Fig. 2. Scatterplot: ICS-treatment duration vs. PC20.
Table 2. Total basement membrane thickness and collagen
III deposition measurements
TBM (µM)
Subepithelial collagen III
expression (%) intensity
LSA (ICS+) 10.52±3.11 59.0±42.6 1.70±1.13
RDA 6.85±1.89 65.29±34.2 1.76±0.93
Controls 3.25±0.96 54.16±39.8 1.66±0.88
p values <0.001* 0.74 0.8
All values are expressed as means ±SD. LSA (ICS+) – long-
standing asthma group treated with ICS, RDA – recently
diagnosed asthma, TBM – total basement membrane.
* Statistically significant.
r = .50562  p = 0.004
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Fig. 3. Scatterplot: astma duration vs. TBM thickness.
Table 3. TGF-β1 expression in the airways
All asthmatics LSA (ICS+) RDA Controls
Number 34 16 18 11
TGF-β1 epithelial expression (%) 10.58 ± 24.2 9.06 ± 24.09 11.94 ± 24.91 25.45 ± 36.70
TGF-β1 subepithelial expression (%) 12.20 ± 24.03 6.56 ± 10.11 17.22 ± 31.21 16.80 ± 27.40
TGF-β1 mucosal intensity* 0.83 ± 0.89 0.81 ± 0.91 0.86 ± 0.90 0.81 ± 0.91
All values are expressed as means ±SD; LSA(ICS+) – long –standing asthma group, RDA – recently diagnosed asthma.
Mucosal intensity – analysis of epithelial and subepithelial area together.
All differents not statistically significant (p>0.05).
Fig. 4. Scatterplot: TGF-β1 epithelial vs. collagen III in LSA group.
Correlation: r = –.5526; p = 0.033
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This study shows that in patients with long-standing
asthma, BHR, probably as a result of corticosteroid
treatment, is significantly decreased compared with
steroid-naive patients with recently diagnosed disease.
This is consistent with a number of previous studies [12,
27, 31]. Moreover, significant correlation between
steroid therapy duration and PC20 values was found. 
In the present study we did not find any differences
in PC20 values with regard to microscopic or macro-
scopic features of mucosal inflammation. Our investiga-
tion was semiquantitative as we did not count the num-
bers of inflammatory cells in the mucosa, but it is in
keeping with previous studies. The results of other stud-
ies on BHR and airway inflammation are largely incon-
sistent, with equal numbers of positive [10] and negative
reports [19]. Our results are consistent with current
beliefs that BHR development depends not only on air-
way inflammation, but also on airway smooth muscle
disorders or other unknown agents [4, 14]. Bousquet et
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Fig. 5. Scatterplot: TGF-β1 epithelial vs. TBM in LSA group.
Correlation: r = –.5333; p = 0.050
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Fig. 6. Scatterplot: TGF-β1 epithelial vs. FEV1 in the RDA group.
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Fig. 7. Photomicrograph of a bronchial biopsy from a patient with
long-standing atopic asthma (staining with toluidine blue) showing
thickening of the basement membrane and deposition of extracel-
lular matrix below the basement membrane.
Fig. 8. Photomicrograph of a bronchial biopsy from a healthy sub-
ject (staining with toluidine blue) showing epithelium, basement
membrane, and a small amount of the subepithelial extracellular
matrix.
Fig. 9. Photomicrograph of a bronchial biopsy from a patient with
long-standing atopic asthma showing immunohistochemical stain-
ing with antibodies to collagen type III (brown collagen III fibers).al. [6] proposed the hypothesis that in asthmatics, BHR
reflects a complex relationship between bronchial
inflammation and remodeling, which makes it difficult
to demonstrate a simple correlation between these
processes and clinical outcome of the disease. In our
study we observed a lack of correlation between the
degree of BHR and subepithelial collagen III deposi-
tion. This is in keeping with previous studies [5].
It is proven that the “true” basement membrane is of
normal structure and thickness in asthmatics. On the
other hand, studies comparing asthmatics with normal
subjects consistently find thickening of the RBM in asth-
matics [2, 9, 11, 15, 17]. There is a wide range of report-
ed values for asthmatics (5.8–30 µm) and control sub-
jects (3.2–7.5 µm). This is probably a matter of the dif-
ferent techniques used.
The role of RBM thickening in BHR development is
not clear and the data are conflicting: thickened RBM
might be responsible for excessive BHR and airway
obstruction, but there are opinions that increased stiff-
ness of the inner wall of the airway due to a thickened
RBM might be a protective mechanism against exces-
sive airway narrowing [18, 30]. 
In the present study we demonstrated thickening of
the TBM in patients with asthma, particularly in
patients in the LSA group. Significant positive correla-
tion in all asthmatics was found between TBM thickness
and asthma duration; however, the corticosteroid thera-
py applied in the LSA group makes an interpretation of
these findings difficult. There are disparities in the pre-
vious reports regarding the effects of steroids on RBM
thickness [17, 23, 25]. In the present study the effect of
corticosteroids on airway remodeling was not directly
investigated. We could only indirectly investigate the
influence of therapy on clinical and immunohistochem-
ical parameters by observing the steroid-treated group
(LSA). Our findings might suggest that corticosteroids
could be insufficiently effective in reducing subepithelial
fibrosis, which is consistent with previous studies [3, 13,
23], but we cannot exclude the possibility that it could be
the result of late treatment introduction.
In the present study we did not find any correlation
between TBM thickness and lung function parameters
in asthmatics; however, it was seen in all patients and
control subjects combined in one group. It is obvious
that for this reason the interpretation of the finding is
difficult and it could imply that RBM thickening might
not be such an important agent affecting airway obstruc-
tion. The lack of association between TBM thickness
and BHR demonstrated here is in keeping with previous
studies [5], but contradictory to others [9, 10, 17]. Our
findings could suggest that both these processes might
be independent results of airway inflammation,
although one cannot exclude the importance of RBM
thickening in BHR development. 
With regard to subepithelial fibrosis assessment, our
findings derived from the collagen III deposition are
quite different from those obtained by the assessment of
TBM thickness. Collagen III is one of the main compo-
nents of the RBM in patients with asthma. However, we
found no correlation between TBM thickness and colla-
gen III deposition in airway mucosa. The different
extents of these two tissue regions could be an explana-
tion, as we investigated collagen III deposition within the
RBM and also in the deeper submucosa. Other investi-
gators demonstrated a lack of such association [11]. In
the present study we did not find any significant differ-
ence in collagen III deposition between the studied
groups. Other authors investigated deeper collagen III
deposition and obtained similar results [31]. We did not
observe any correlation between collagen III deposition
and clinical outcome. Considering all the limitations of
our study (e.g. small population), our results showing
a lack of significant correlation between TBM thickness
or collagen III deposition and lung function or BHR
could imply that these remodeling components may not
be crucial for asthma pathogenesis and clinical outcome.
TGF-β is a profibrotic cytokine which reveals the
prevailing anti-inflammatory activity. There is a hypoth-
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Fig. 10. Photomicrograph of a bronchial biopsy from a patient with
recently diagnosed asthma showing immunohistochemical staining
with antibodies to collagen type III (brown collagen III fibers).
Fig. 11. Photomicrographs of a bronchial biopsy from a healthy
subjectc showing immunohistochemical staining with antibodies to
collagen type III (brown collagen III fibers).esis of TGF-β signaling disorders within asthmatic air-
ways which could result in airway inflammation mainte-
nance [1]. The expression of TGF-β in asthmatics varies
among investigators [8, 17, 23, 30]. Magnan et al. [22]
reported decreased TGF-β expression in the asthmatic
epithelium, while others (e.g. Vignola) observed elevat-
ed TGF-β expression in the epithelium of asthmatics
[30]. In our study we did not find any significant differ-
ence in epithelial and submucosal TGF-β1 expression
between the two groups of asthmatics and control sub-
jects. The results of the study confirm those of other
investigators [11, 17]. However, it is worth mentioning
that we showed an insignificant tendency towards high-
er epithelial TGF-β1 expression in healthy subjects com-
pared with asthmatics. There is some evidence that the
epithelial TGF-β distribution might be the main normal
source of that growth factor in the airways, where it
could play an anti-inflammatory role in maintaining the
tissue homeostasis [8, 21]. In the present study the pro-
tective role of TGF-β1 might be confirmed by the posi-
tive correlation between TGF-β1 epithelial immunore-
activity and lung function and the negative correlation
between that TGF-β1 distribution and collagen III depo-
sition. These findings suggest that TGF-β1 in the epithe-
lium might exert a different role from the one it exerts
in the ECM, as these correlations were not seen regard-
ing submucosal TGF-β1 immunoreactivity. In the pre-
sent study the other agent making the interpretation dif-
ficult could be the corticosteroid therapy introduced in
LSA-group, as the influence of ICS on TGF-β1 expres-
sion is not clear [3, 21, 24].
Taking into account all the limitations of our study
(e.g. partially semiquantitative methodology), we cannot
exclude that airway inflammation and BHR, two major
features of asthma, might be loosely related to each
other. Obviously, performing cell counts would be neces-
sary to confirm this. Subepithelial fibrosis remains a fact
in asthmatic airways, but it role and its linkage with clin-
ical parameters are still unclear and further studies are
necessary to explain them as well as the influence of cor-
ticosteroid treatment on remodeling components. RBM
thickening in patients with asthma is just one of a num-
ber of remodeling components, and simple relationships
between this parameter and clinical outcome of the dis-
ease are difficult to find; however, it is a marker differ-
entiating asthmatics and healthy subjects. TGF-β1 acts in
a complex multidirectional net of mediators.
Homeostasis within the net and the cooperation of
cytokines or growth factors influences its final result. As
we suggest, it can have different activity depending on
the distribution and the microenvironment.
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